Mayu 2022: Trametinib na iya zama sabon ma'auni na kulawa don maimaituwa, ƙananan ciwon daji na ovarian (Makinist). According to study findings published in the February 2022 issue of The Lancet, trametinib beat both chemotherapy and anti-estrogens like tamoxifen by around 52 percent, adding six months of progression-free (period during which the cancer did not advance) survival for patients.
A cikin mata 260 da ke fama da ciwace-ciwacen ƙwayar cuta na kwai waɗanda a baya sun karɓi chemotherapy, masu bincike daga Amurka da Burtaniya sun kwatanta trametinib na baka sau ɗaya kowace rana zuwa ɗaya daga cikin matakan kulawa guda biyar (ko dai chemotherapy ko magungunan isrogen). Lokacin da aka kwatanta da jiyya na yau da kullum, mahalarta trametinib sun nuna amsa sau hudu mafi girma ga farfadowa bayan watanni 15. Trametinib ya fi duk sauran jiyya, yana rage jinkirin ci gaban cuta na tsawon watanni 13 (a kan watanni bakwai don daidaitaccen magani). Kurjin fata, anemia, hawan jini, gudawa, da kasala wasu daga cikin illar illar da ke tattare da maganin trametinib.
Low-grade serous ciwon daji na ovarian is a difficult-to-treat invasive form of ovarian cancer marked by strong hormone receptor activation, genetic alterations, and poor chemotherapy response. Until now, the cancer toolbox lacked effective therapeutic options for patients with low-grade serous ovarian cancer. According to an editorial accompanying the report, 70% of these women will recur, with only 5% responding to further chemotherapy.
